Amylyx Pharmaceuticals, Inc.
AMLX
株式のランク
#4396
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
株価
$28.57
時価総額
$3.59B
変化（1日）
4.54%
変化（1年）
85.89%
国
US
取引 Amylyx Pharmaceuticals, Inc. (AMLX)
カテゴリー
Healthcare
Amylyx Pharmaceuticals, Inc.（AMLX）の利益
Jun 2026 時点の利益 TTM: $-152.05M
Amylyx Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は $-152.05M です。2023 年には $54.30M の利益を上げ、これは 2022 年の利益 $-197.60M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Amylyx Pharmaceuticals, Inc. の利益の推移（2019 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-152.05M | -49.68% |
| 2024 | $-302.14M | -656.45% |
| 2023 | $54.30M | -127.48% |
| 2022 | $-197.60M | 124.72% |
| 2021 | $-87.93M | 107.97% |
| 2020 | $-42.28M | 208.25% |
| 2019 | $-13.72M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -3,569.28% |
US
|
|
| $-3.09B | 1,930.31% |
US
|
|
| $-4.02B | 2,541.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,382.93% |
NL
|
